Pediatric CRRT: The Prescription Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine.

Slides:



Advertisements
Similar presentations
Neonatal and Infant CRRT
Advertisements

Renal Replacement Therapy Options for Children
Pediatric CRRT: Terminology and Physiology
CVVH vs CVVHD Does it Matter?
So how do I dose this drug “X” Timothy E Bunchman
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
EDWARD WELSH MARCH Dialysis Adequacy (?).
Continuous Renal Replacement Therapy. Why continuous Therapies? Continuous therapies closely mimic the GFR of native kidneys Large amounts of fluid.
ECMO in CRRT – What are the Data?
HEMODIALYSIS ADEQUACY HEMODIALYSIS ADEQUACY Laurie Vinci RN, BSN, CNN Laurie Vinci RN, BSN, CNN September 17, 2011 September 17, 2011.
Pediatric Bone Marrow Transplant Recipients with Acute Kidney Injury Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine.
Dr Umut Selda Bayrakçı Yıldırım Beyazıt University, Dept of Pediatric Nephrology, Ankara, Turkey * Basics of CRRT Terminology.
Pediatric Bone Marrow Transplant Recipients with Acute Renal Failure Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine.
Troubleshooting Issues in CVVH Timothy L. Kudelka RN, BSN Pediatric Dialysis Program C.S. Mott Children’s Hospital University of Michigan.
AKI Definitions Stuart L. Goldstein, MD Professor of Pediatrics University of Cincinnati College of Medicine Director, Center for Acute Care Nephrology.
RENAL REPLACEMENT THERAPY
Pediatric Acute Renal Failure: CRRT/Dialysis Outcome Studies Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine.
Vascular Access for CRRT Timothy E Bunchman Professor & Director Helen DeVos Children’s Hospital Grand Rapids, MI (Thanks to Rick Hackbarth MD for his.
Pediatric CRRT: The Prescription
Acute Renal Replacement Therapy for the Infant Jordan M. Symons, MD University of Washington School of Medicine Children’s Hospital & Regional Medical.
The Prospective Pediatric CRRT (ppCRRT) Registry Stuart L. Goldstein, MD Principal Investigator and Founder Timothy E Bunchman Helen DeVos Children’s Hospital.
Practical Considerations for CRRT Helen Currier RN, BSN, CNN Nancy McAfee RN, BSN, CNN.
A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.
Sean M Bagshaw, MD, MSc Division of Critical Care Medicine Faculty of Medicine and Dentistry, University of Alberta 1 st International Symposium on AKI.
Anticoagulation in CRRT
PCRRT PRESCRIPTIONS in ARF Patrick D. Brophy MD University of Michigan Pediatric Nephrology.
Stuart L. Goldstein, MD Professor of Pediatrics
Major Published Clinical Trials in AKI: What do they Really Mean? Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Tomáš Zaoral1, Michal Hladík1, Jana Zapletalová2 1Pediatric intensive care unit, Department of Pediatrics,Faculty of Medicine, University Hospital Ostrava.
Is There a Rationale To Use CRRT For Treating Sepsis? James D. Fortenberry MD, FCCM, FAAP Pediatrician in Chief Children’s Healthcare of Atlanta Professor.
Use of CRRT in ECMO: Is It Valuable? James D. Fortenberry MD, FCCM, FAAP Associate Professor of Pediatrics Emory University School of Medicine Director,
Excessive fluid is not needed: So why is Dr. Durward so wasteful? Timothy E Bunchman MD Professor & Director Pediatric Nephrology
Major Clinical Trials in AKI Michael Zappitelli, MD, MSc Montreal Children's Hospital McGill University Health Centre.
Pediatric CRRT Programs: A tool-kit for evaluation Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Common Prescription Errors in Pediatric CRRT: a “Top 10 List” Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital.
THE EFFECT OF TIMING OF INITITIATION OF CRRT ON PATIENTS REQUIRING EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) Asif Mansuri, MD, MRCPI Fellow, Division.
University of Pittsburgh
David Askenazi MD, MSPH Associate Professor of Pediatrics 2Smaller Circuits for Smaller Patients Improving Renal Support with Aquadex™ Machine.
Citrate Anticoagulation
Raghavan Murugan, MD, MS, FRCP Associate Professor of Critical Care Medicine, and Clinical & Translational Science Core Faculty, Center for Critical Care.
Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.
Complications of Pediatric CRRT Theresa A. Mottes RN Pediatric Dialysis/Research Nurse C.S. Mott Children’s Hospital University of Michigan.
PCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics.
Dosing of Anti-Fungal agents on CRRT Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children’s Hospital of Richmond.
PCRRT Tûr'mə-nŏl'ə-jē Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Cytokine and Soluble Fas Ligand Response in Children with Septic Acute Renal Failure (ARF) on CVVH Paden ML, Fortenberry JD, Rigby MR, Trexler AM, Heard.
Continuous Renal Replacement Therapy Developed by: Critical Care and Hemodialysis Educators, February 2009 King Faisal Specialist Hospital and Research.
Convection (CVVH) is Better! Timothy E Bunchman MD Professor & Director Pediatric Nephrology
Use of CRRT in ECMO: Is It Valuable? James D. Fortenberry MD, FCCM, FAAP Associate Professor of Pediatrics Emory University School of Medicine Director,
CONTINUOUS RENAL REPLACEMENT THERAPY
CRRT Fundamentals Pre- and Post- Test
CRRT (Continuous Renal Replacement Therapy)
When fluids go wrong: CRRT in fluid overload
Access for Pediatric CRRT
Devices use for Neonatal AKI
Prescriptions in CRRT Timothy E Bunchman MD Professor & Director
Vascular Access and Infused Fluids for Pediatric CRRT
DEBATE: Timing of CRRT in Critical Care
CRRT Fundamentals Pre- and Post- Test Answers
OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer,
Objectives Early initiation of continuous renal replacement therapy
T.Zaoral,M.Hladík, M.Sádlo, V.Vobruba
What are we trying to dialyse?
Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.
Pediatric CRRT Terminology
Basics of CRRT: Terminology
J Foland, J Fortenberry, B Warshaw,
Children’s Memorial Hospital Northwestern University
Plasmapheresis With (and Without) CRRT
Case 20 kg child with sepsis and oliguria on norepinephrine with a BP of 95/45 Vent at 70% FIO2 and a PEEP of 8 FO at 15% K of 6 meq/dl and a BUN of 100.
Presentation transcript:

Pediatric CRRT: The Prescription Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine

What’s in a CRRT Prescription? Indication (Why? Who? When?) Technical Aspects (What?)  Fluids (Symons)  Anticoagulation (Brophy)  Access (Hackbarth) CRRT Delivery (How?)  Blood pump flow rates  Modality  Priming  Dose

Why CRRT in AKI? Critically ill patient Advantages  Slower blood flows  Slower UF rates  UF rates can be prescriptive (versus PD)  Adjust UF rates with hourly patient intake  Increased cytokine (bad humors) removal? Disadvantages  Increased cytokine (good humors) removal?  Non-dialysis personnel with many other bedside responsibilities required to monitor circuit

When Should CRRT Be Started? Standard AKI criteria not responsive to medical therapy OR only preventable with limiting adequate nutrition  Uremia  Hyperkalemia  Acidosis  Fluid Overload Prevention of worsening fluid overload?

Timing of Pediatric RRT No adequate definition for “timing of initiation” Absence of a generally accepted, validated and applied AKI definition has impeded the adequate investigation of this question The decision to initiate RRT affected by  Strongly held physician beliefs  Patient characteristics  Organizational characteristics

Retrospective evaluation of 226 children who received RRT for AKI from Pressor use surrogate marker for patient severity of illness Survival defined at PICU discharge

Retrospective review of all patients who received CVVH(D) in the Texas Children’s Hospital PICU from February 1996 through September 1998 (32 months) Pre-CVVH initiation data:  Age  Primary disease leading to need for CVVH  Co-morbid diseases  Reason for CVVH  Fluid intake (Fluid In) from PICU admission to CVVH initiation  Fluid output (Fluid Out) from PICU admission to CVVH initiation  GFR (Schwartz formula) at CVVH initiation

Percent Fluid Overload Calculation % FO at CVVH initiation = [ Fluid In - Fluid Out ICU Admit Weight ] * 100% Fluid In = Total Input from ICU admit to CRRT initiation Fluid Out = Total Output from ICU admit to CRRT initiation

22 pt (12 male/10 female) received 23 courses (3028 hrs) of CVVH (n=10) or CVVHD (n=12) over study period. Overall survival was 41% (9/22). Survival in septic patients was 45% (5/11). PRISM scores at ICU admission and CVVH initiation were /- 5.7 and /- 9.0, respectively (p=NS). Conditions leading to CVVH (D)  Sepsis (11)  Cardiogenic shock (4)  Hypovolemic ATN (2)  End Stage Heart Disease (2)  Hepatic necrosis, viral pneumonia, bowel obstruction and End-Stage Lung Disease (1 each)

Survival curve demonstrates that nearly 75% of deaths occurred less than 25 days into the ICU course

Lesser % FO at CVVH (D) initiation was associated with improved outcome (p=0.03) Lesser % FO at CVVH (D) initiation was also associated with improved outcome when sample was adjusted for severity of illness (p=0.03; multiple regression analysis)

N=113 *p=0.02; **p=0.01

Group Fluid Overload Hazard Ratio (95% CI)P All Subjects <10% >10%3.02 ( ) N = 77

Kaplan-Meier survival estimates, by percentage fluid overload category

The Evolution of Idea to Practice Paradigm Single center study Registry Randomized Trial

Prospective Pediatric CRRT (ppCRRT ) Registry: Phase 1 Design Collect prospective data from 10 pediatric centers treating 15 to 20 patients annually (376 patients over 5 years) Each center follows own institutional practice  Patient selection  Initiation and termination  Anti-coagulation protocols  Convection versus diffusion versus hemodiafiltration  Fluid composition

Seven center study from the ppCRRT Registry 116 patients with MODS PRISM 2 score used to assess patient severity of illness Survival defined at PICU discharge

 77% of non-survivors die within 3 weeks of ICU admission  Survival rates similar by CRRT modality (H 57%), (DF 53%), (HD 50%)  Survival rates similar for patients on: 0- 1 (53%), 2 (54%) or 3+ (39%) pressors  Survival rates better for patients with: 20% FO (40%) at CRRT initiation (p<0.001)

The PCRRT Prescription: How? Blood pump flow rates Membranes Priming Modality Dose UF rates

Blood flow rates vary by patient size  Mean 5 ml/min/kg  CRRT clearance not limited by Qb 50% of ppCRRT patients received some convection

Pediatric CRRT Circuit Priming Heparinized (5000 units/L) for most patients Smaller patients require blood priming to prevent hypotension/hemodilution  Circuit volume > 10-15% patient blood volume  Packed RBCs Citrated – low ionized calcium Acid load Potassium load

Bradykinin Release Syndrome Mucosal congestion, bronchospasm, hypotension at start of CRRT Resolves with discontinuation of CRRT Thought to be related to bradykinin release when patient’s blood contacts hemofilter  Most common with AN-69 membranes Exquisitely pH sensitive

Technique Modifications to Prevent Bradykinin Release Syndrome Buffered system  THAM, CaCl, NaBicarb to PRBCs Bypass system  prime circuit with saline, run PRBCs into patient on venous return line Recirculation system  recirculate blood prime against dialysate

PRBC Waste

D Recirculation Plan: Qb 200ml/min Qd ~40ml/min Time 7.5 min Normalize pH Normalize K +

Does Modality Make A Difference? Equal clearance of smaller molecules Middle and large molecule clearance enhanced by convection

Creatinine 113 D Urea 60 D Glucose 180 D Vit. B 12 1,355 D  2-M 11,800 D Albumin 66,000 D IgG 150,000 D Membrane Selectivity Courtesy of J. Symons

Clearance: Convection vs. Diffusion

Solute Molecular Weight and Clearance Solute (MW)Sieving Coefficient Diffusion Coefficient Urea (60)1.01 ± ± 0.07 Creatinine (113)1.00 ± ± 0.06 Uric Acid (168)1.01 ± ± 0.04* Vancomycin (1448)0.84 ± ± 0.04** *P<0.05 vs sieving coefficient **P<0.01 vs sieving coefficient

Flores FX et al: CRRT 2006 abstract

ppCRRT Pediatric Sepsis Outcome Data 57/102 (56%) pts survived. Ventilated pts had similar survival rate as non- ventilated pts (53% vs. 68%, p=0.1). There was no significant difference in the survival rate among CRRT modalities. Tendency toward better survival with convective therapies Flores FX et al: CRRT 2006 abstract

Survival Based on CRRT Modality? Confounded  Center  Timing of initiation  Sepsis definition not standardized Suggestive  If all else equal, why not convect? Flores FX et al: CRRT 2006 abstract

Dialysate/ Ultrafiltration Rates The UF rate/plasma flow rate [=BFRx(1-HCT)] ratio should < in order to avoid filter clotting (Golper AJKD 6: ,1985) Dialysate flow rates ranging from ml/min/m 2 (~2000ml/1.72m 2 /hr) are usually adequate (experiential but consistent with adult data)

Median survival  Group 1 (19 days)  Group 2 (33 days)  Group 3 (46 days) Groups 2 and 3 with longer survival than Group 1

Minimum UF rates > 35 ml/kg/hr Translates to approximately 2000ml/1.73m2/hour for children

Dose: Pediatric CRRT No published data to suggest an adequate or optimal CRRT dose in children Small molecule clearance and electrolyte homeostasis is generally easy to achieve Is more better?  Nutrition balance (what are we removing that we’d like to leave behind?)